ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 770,95
0,48%
Dow Jones
44 025,81
1,24%
DAX
21 042,00
0,18%
Brent Oil
78,585
-0,21%
Bitcoin
105 897,98
-0,26%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Agenus Inc (AGEN)

  7. Agenus Inc (AGEN) Actualités

AGEN

Agenus (AGEN)

Agenus Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AGEN
DateHeureSourceTitreSymboleSociété
02/01/202522h05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
18/12/202413h30Business WireAgenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric CancersNASDAQ:AGENAgenus Inc
05/12/202413h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
05/12/202413h30Business WireAgenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce CostsNASDAQ:AGENAgenus Inc
27/11/202414h15Business WireAgenus Secures $22 Million Mortgage and Announces Strategic Operational RealignmentNASDAQ:AGENAgenus Inc
15/11/202401h58Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AGENAgenus Inc
12/11/202422h58Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGENAgenus Inc
12/11/202413h00Business WireAgenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL DevelopmentNASDAQ:AGENAgenus Inc
08/11/202420h18Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:AGENAgenus Inc
07/11/202416h00Business WireAgenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024NASDAQ:AGENAgenus Inc
05/11/202413h30Business WireAgenus to Provide Third Quarter 2024 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
04/11/202411h45PR Newswire (US)The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Agenus Inc.(AGEN) ShareholdersNASDAQ:AGENAgenus Inc
31/10/202410h45PR Newswire (US)Agenus Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AGENNASDAQ:AGENAgenus Inc
17/10/202411h45PR Newswire (US)Shareholders that lost money on Agenus Inc.(AGEN) should contact The Gross Law Firm about pending Class Action - AGENNASDAQ:AGENAgenus Inc
14/10/202411h45PR Newswire (US)Shareholders that lost money on Agenus Inc.(AGEN) Urged to Join Class Action - Contact The Gross Law Firm to Learn MoreNASDAQ:AGENAgenus Inc
10/10/202411h45PR Newswire (US)Agenus Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before November 5, 2024 to Discuss Your Rights - AGENNASDAQ:AGENAgenus Inc
07/10/202411h45PR Newswire (US)Agenus Inc. Class Action: The Gross Law Firm Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024 - AGENNASDAQ:AGENAgenus Inc
26/09/202411h45PR Newswire (US)AGEN LAWSUIT ALERT: The Gross Law Firm Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNASDAQ:AGENAgenus Inc
19/09/202411h45PR Newswire (US)Contact The Gross Law Firm by November 5, 2024 Deadline to Join Class Action Against Agenus Inc.(AGEN)NASDAQ:AGENAgenus Inc
13/09/202416h00Business WireBotensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024NASDAQ:AGENAgenus Inc
11/09/202420h25PR Newswire (US)AGEN INVESTOR ALERT: Edelson Lechtzin LLP Urges Agenus, Inc. (NASDAQ: AGEN) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class ActionNASDAQ:AGENAgenus Inc
09/09/202413h30Business WireBotensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024NASDAQ:AGENAgenus Inc
03/09/202413h30Business WireAgenus to Participate in September Investor ConferencesNASDAQ:AGENAgenus Inc
08/08/202422h47Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AGENAgenus Inc
08/08/202422h45Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
08/08/202413h00Business WireAgenus Announces Appointment of Tom Harrison to Board of DirectorsNASDAQ:AGENAgenus Inc
08/08/202413h00Business WireAgenus Reports Second Quarter 2024 Operational and Financial ResultsNASDAQ:AGENAgenus Inc
07/08/202416h58Business WireAgenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant CancersNASDAQ:AGENAgenus Inc
26/07/202413h00Business WireAgenus to Provide Second Quarter 2024 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
18/07/202413h00Business WireAgenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal CancerNASDAQ:AGENAgenus Inc
 Showing the most relevant articles for your search:NASDAQ:AGEN

Dernières Valeurs Consultées

EU
AI
Air Liquide
COIN
ETHUSD
Ethereum
EU
CS
Axa
EU
RI
Pernod Ricard
USI
USTECH100
US Tech 100
EU
BNP
BNP Paribas
FTSE
UKX
FTSE 100
EU
VIV
Vivendi
EU
DG
Vinci
EU
ML
Michelin
EU
VK
Vallourec
NYSE
MCD
McDonalds
EU
LR
Legrand
EU
GLE
Societe Generale
NYSE
MRK
Merck
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés